1Carver BS, Bianco FJ Jr, Scardino PT, et al. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer[J]. J Uroi,2006,76(2) : 564-568.
2Roche JB, Malavaud B, Soulie M. Pathological stage T3 prostate cancer after radical prostatectomy: a retrospective study of 246 eases[J]. Prog Urol,2008,18(9):586-594.
3Morgan SC, Waldron TS, Eapen L, et al. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis[J]. Radiother Oncol,2008,88(1) :1-9.
4Xylinas E, Misra V, Comperat E, et al. Oncologic and functional outcomes after radical prostatectomy in T3 prostate cancer [J]. Prog Urol, 2009,19(5) : 285-290.
5Xylinas E, Drouin SJ, Comperat E, et al. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience[J]. BJU Int,2009,103 (9) :1173-1178.
6Vuky J, Porter C, Isacson C. Phase Ⅱ trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high risk, locally advanced prostate cancer[J]. Cancer,2009,115(4) : 784-791.
7Palisaar RJ, Noldus J. The role of surgery in locally advanced prostate eancer[J]. Urologe A, 2008,47 (11) : 1417-1423.
8Van Poppel H, Joniau S, Haustermans K. Role of surgery in stade cT3-4 NOM0 prostate cancer[J]. Cancer Radiother, 2007,11 (8) :483-489.
9Francini G, Paolelli L, Franeini E, et al. Effect of neoadju rant epirubicin and total androgen blockade on complete path ological response in patients with clinical stage T3/T4 pros tare cancer[J]. Eur J Surg Oncol,2008,34(2):216-221.
10Casey JT, Meeks JJ, Greco KA, et al. Outcomes of locally advanced (T3 or greater) prostate cancer in men undergoing robot-assisted laparoscopic prostatectomy [J]. J Endourol, 2009,23(9) :1519-1522.
8Murtola TJ,Visakorpi T,Lahtela J,et al.Statins and prostatecancer prevention:Where we are now,and future directions.NatClin Pract Urol,2008,5(7):376-387.
9Twiddy AL,Leon CG,Wasan KM.Cholesterol as a potential tar-get for castration-resistant prostate cancer.Pharm Res,2011,28(3):423-437.
10Getzenberg RH.Statins and the risk of prostate cancer or benignprostatic hyperplasia:Biological plausibility.J Urol,2010,184(2):415-416.
